H. Stewart Parker, President and Chief Executive Officer
Stewart Parker managed the formation of Targeted Genetics as a wholly owned subsidiary of Immunex Corporation (Immunex was subsequently acquired by Amgen) and has served as president, chief executive officer and a director of Targeted Genetics since our spinout from Immunex in 1992. She served in various capacities at Immunex from August 1981 through December 1991, most recently as vice president, corporate development. Ms. Parker also served as president and a director of Receptech Corporation, a company formed by Immunex in 1989 to accelerate the development of soluble cytokine receptor products, from February 1991 to January 1993. She serves on the board of directors and the executive committee of BIO, the primary trade organization for the biotechnology industry, and as a director of several companies and non-profit organizations. Ms. Parker received her B.A. and M.B.A. from the University of Washington.
Barrie J. Carter, Ph.D., Executive Vice President and Chief Scientific Officer
Barrie Carter has served as an executive vice president of Targeted Genetics since August 1992. Dr. Carter has served as chief scientific officer since January 2001 and was director of research and development from August 1992 to December 2000. Before joining Targeted Genetics he was employed for 22 years by the National Institutes of Health, or NIH. He served as chief of the laboratory of molecular and cellular biology in the National Institute for Diabetes and Digestive and Kidney Diseases from 1982 to 1992. From 1995 to 2000, he was an affiliate professor of medicine at the University of Washington Medical School. Dr. Carter received his B.Sc. (Honors) from the University of Otago, Dunedin, New Zealand and his Ph.D. in biochemistry from the University of Otago Medical School. He then spent a period of postdoctoral training at the Imperial Cancer Research Fund Laboratories in London before joining the NIH. His long-term research interests are in the molecular biology of viruses, development of AAV vectors and gene therapy. Dr. Carter serves on the editorial board of Human Gene Therapy and Virology, and as an associate editor of Molecular Therapy. He also serves on the board of directors of the American Society of Gene Therapy.
David J. Poston, Vice President, Finance, Chief Financial Officer, and Treasurer
David Poston joined Targeted Genetics Corporation in 1999 and served as the company’s senior director of finance and accounting from 2001 through 2005 and as the finance director from 1999 to 2001. Mr. Poston leads the operations of the finance and accounting groups, internal and SEC financial reporting, budgeting, project cost accounting, general accounting, internal financial controls, audit committee coordination, lease financing, treasury and insurance matters and financial aspects of corporate collaborations. Mr. Poston helped establish and later spin-off CellExSys, Inc., as a vehicle for capitalizing on Targeted Genetics’ cell therapy technologies, serving as secretary and treasurer of CellExSys from its founding in 2000 until its sale in 2004. Prior to joining Targeted Genetics, he served as controller of Corixa Corporation, controller and assistant treasurer of Todd Shipyards Corporation and in financial management capacities at Rocket Research Corporation (now General Dynamics). Mr. Poston has over twenty years of financial experience, has had primary responsibility for public company financial disclosure matters since 1993 and started his career in public accounting at KPMG in 1985. Mr. Poston graduated from the University of Puget Sound with a B.S. in accounting, a minor in mathematics and as the Norton Clapp Arete Scholar.
Pervin Anklesaria, Ph.D., Vice President Therapeutic Development
Pervin Anklesaria joined Targeted Genetics Corporation in 1993 and currently leads the clinical, regulatory, quality, pre-clinical and project management groups. Dr. Anklesaria also served as Vice President of Research, Director of Research and Development Administration and Staff Scientist with the Company prior to assuming her current position in 2002. Prior, Dr. Anklesaria was an Assistant Professor in the Department of Radiation Oncology at the University Massachusetts Medical Center where studied stem cell biology and managed the laboratory and staff activities as an independent investigator. Dr. Anklesaria received a B.S. in Microbiology and Chemistry, a M.S. in Biophysics and a Ph.D. in Cell Biology from the University of Bombay, India.
Richard W. Peluso, Ph.D., Vice President, Process Development
Richard Peluso has been with Targeted Genetics since 2000. Before joining Targeted Genetics he worked for Genovo, a private gene therapy company near Philadelphia. Dr. Peluso worked for two years prior to Genovo for Quality Biotech/ViroMed, a contract biosafety testing company. Prior to that he held academic positions at several medical schools, the most recent the Mount Sinai School of Medicine in New York, where he was an associate professor and ran an academic research lab. Richard obtained a PhD from The Rockefeller University in New York in Virology with Professors Purnell Choppin and Robert Lamb. Richard serves on the editorial board of Virology and Human Gene Therapy.
B.G. Susan Robinson, Vice President, Business Development
Susan Robinson leads the licensing and partnering activities for Targeted Genetics and is integrally involved in the M&A activities and strategic planning functions for the company. Prior to joining Targeted Genetics in March 2000, Ms. Robinson was employed as Director, Business Development at Genzyme Molecular Oncology , a tracking stock of Genzyme Corporation. In her business development roles she has completed multiple academic and corporate technology licenses, sponsored research agreements, pharma/biotech product development collaboration agreements and an acquisition. Prior to Genzyme, and over a nine year period, Ms. Robinson held increasingly responsible positions in corporate development and Corporate Communications for two biotech companies. In these positions, she was involved in strategic planning, public and private financing efforts, interactions with sell and buyside analysts and the creation and delivery of investor presentations and press releases. Ms. Robinson graduated with a B.S. in Biology from Yale University in 1983.
|
